Background: Pre-exposure prophylaxis (PrEP), using daily oral tenofovir disoproxil fumarate (TDF) or combination emtricitabine (FTC)/TDF, is a proven HIV prevention strategy. Observational studies have suggested that the injectable contraceptive depot medroxyprogesterone acetate (DMPA) may increase the risk for HIV acquisition among women. Whether PrEP is efficacious for HIV prevention among women using DMPA has not been evaluated previously.
Methodology: In a randomized, placebo-controlled trial of PrEP among Kenyan and Ugandan HIV serodiscordant couples (the Partners PrEP Study), we estimated the efficacy of PrEP (TDF or FTC/TDF) for HIV prevention among HIV uninfected women using DMPA. HIV uninfected members of the couples were seen monthly and study visits included HIV testing, study medication provision, and adherence counseling. Contraception was not required but women were counseled to delay pregnancy until after this PrEP safety and efficacy study, and a variety of contraceptives were offered on-site, free-of-charge.
Results: 1785 HIV uninfected women participated in the trial, of whom 901 (50.5%) used DMPA at some point during follow-up, including 486 who were using DMPA at enrollment and 415 who initiated DMPA during follow-up. During follow-up, 45 women acquired HIV, of whom 15 (33.3%) were using DMPA at the time of HIV acquisition. Among women using DMPA, HIV incidence was 1.24 per 100 person-years for women assigned to active TDF or FTC/TDF PrEP and 3.75 per 100 person-years among women assigned placebo, translating into a 72% reduction in the risk of HIV acquisition from PrEP among women using DMPA (hazard ratio 0.28, 95% confidence interval 0.10 – 0.83, p=0.02). Sensitivity analyses with varied definitions of DMPA use, including DMPA use as reported at enrollment and a prolonged effect of DMPA for 70 days after last reported use, had similar findings.
Conclusions: PrEP is efficacious for HIV prevention among women using DMPA, suggesting PrEP could mitigate the potential increased HIV acquisition risk that has been associated with DMPA use in some observational studies. Strategies to integrate PrEP use and family planning counseling should be prioritized for women at high risk of HIV infection.